Keith Dredge
Keith is currently Director of Drug Development at Progen Pharmaceuticals Ltd, an oncology-focused biotech based in Brisbane. In this role, he is responsible for the progression of drug candidates through Progen’s pipeline. Keith has authored over 30 peer-reviewed articles including several on Progen’s PG545 in Molecular Cancer Therapeutics, PLoS One, British Journal of Cancer and Investigational New Drugs. Previously, Keith held a management position at TetraQ, a GLP-recognised contract research organisation at The University of Queensland (UQ) and academic positions at UQ and at St. George’s University of London, UK where he published the first articles on Celgene’s Revlimid® and Pomalyst®, now approved anti-cancer drugs. Keith obtained his Ph.D. in Pharmacology from the National University of Ireland, Galway and B.Sc. (Hons) in Toxicology from the Athlone Institute of Technology (Ireland). Keith is also a member of the American Association of Cancer Research (AACR)and a UK and European Registered Toxicologist(ERT).
Abstracts this author is presenting: